Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $1,000.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target increased by Cantor Fitzgerald from $925.00 to $1,000.00 in a report published on Monday, Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Regeneron Pharmaceuticals’ FY2024 earnings at $35.16 EPS.

REGN has been the subject of several other reports. Bank of America lifted their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an underperform rating in a research report on Friday, April 12th. UBS Group lifted their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a buy rating in a research report on Wednesday, April 17th. JPMorgan Chase & Co. lifted their price objective on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an overweight rating in a research report on Monday, June 17th. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating for the company in a research report on Thursday, July 11th. Finally, Truist Financial reissued a buy rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of Moderate Buy and an average target price of $1,074.95.

Regeneron Pharmaceuticals Stock Up 0.5 %

Shares of REGN opened at $1,060.86 on Monday. Regeneron Pharmaceuticals has a 52 week low of $721.51 and a 52 week high of $1,106.16. The stock has a market capitalization of $116.90 billion, a price-to-earnings ratio of 31.34, a PEG ratio of 2.22 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The stock has a fifty day moving average of $1,030.00 and a 200-day moving average of $974.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the transaction, the executive vice president now owns 37,937 shares in the company, valued at approximately $41,311,496.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Joseph J. Larosa sold 1,866 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now owns 37,937 shares in the company, valued at approximately $41,311,496.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The disclosure for this sale can be found here. In the last quarter, insiders sold 65,074 shares of company stock worth $64,546,123. Insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. West Paces Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the period. Crewe Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $28,000. MCF Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares during the period. Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $33,000. Finally, Family Firm Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.